Darwin’s Medicine is the sequel to Brian D. Smith’s influential and critically acclaimed Future of Pharma (Gower, 2011). Whereas the earlier book predicted the evolution of the pharmaceutical market and the business models of pharmaceutical companies, Darwin’s Medicine goes much deeper into the drivers of industry change and how leading pharmaceutical and medical technology companies are adapting their strategies, structures and capabilities in practice.
Through the lens of evolutionary science, Professor Smith explores the speciation of new business models in the Life Sciences Industry. This sophisticated and highly original approach offers insights into:
These insights map out the industry’s complex, changing landscape and provide an invaluable guide to those firms seeking to survive and thrive in this dynamic market.
The book is essential reading for anyone working in or studying the pharmaceutical, medical technology and related sectors. It provides a unique and novel way of making sense of the transformation we can see going on around us and a practical, focused approach to managing a firm’s evolutionary trajectory.
Part 1: The Future of Pharma - Reprise
1. Introduction and an Invitation to Skip a Chapter
2. An Important Industry at Risk
3. The Best Idea Anyone Has Ever Had
4. The Biologists Got There First
5. Applying Evolutionary Theory to the Pharmaceutical and Medical Technology Sectors
6. Explaining the Industry’s Past
7. Predicting the Future of Pharma and Medtech
8. Practical Implications for an Evolving Industry
9. Watching the Future Unfold
Part 2: An Immeasurably Superior Power
10. Introduction: The Emergent Pressures of Selection
11. Selection Pressures Emerging from the Social Environment
12. Selection Pressures Emerging from the Technological Environment
13. Asking the Right Questions
Part 3: Evolution is Cleverer Than You Are
14. Introduction: Orgel’s Second Law
15. Technological Innovator Species Emerging in the Government Payer Habitat
16. Technological Innovator Species Emerging in Patient Payer Habitats
17. Operationally Excellent Species Emerging in the Government Payer Habitat
18. Operationally Excellent Species Emerging in Patient Payer Habitats
19. Customer Intimate Species Emerging in the Government Payer Habitat
20. Customer Intimate Species Emerging in Patient Payer Habitats
21. A Big Bang of Life Science Business Models
Part 4: Guiding the Blind Watchmaker
22. Introduction: From Description to Prescription
23. Which Fitness Peak(s) Should We Climb?
24. What Capabilities Does Our New Business Model Need?
25. How Should We Design a Capable Holobiont?
26. How Do We Build Our Core Capabilities?